The legal action centers on disclosures made on May 5, 2026, when the medical device manufacturer revealed its second-quarter results. Rather than the anticipated flat performance or minor 2% dip, revenue plunged by over 14%. The company pointed to significant weakness in U.S. pen needle sales, a core segment that forced leadership to lower its financial outlook for the remainder of the year.

Pomerantz LLP is currently organizing the class action, inviting shareholders who acquired securities during the specified class period to participate. Those seeking to serve as Lead Plaintiff must file their requests with the Court by August 17, 2026. The firm, which maintains a global presence, is investigating whether Embecta’s officers or directors misled the market regarding the company’s underlying business health prior to the May collapse.